Drug Profile
Voclosporin eye disorder therapeutic - Aurinia Pharmaceuticals
Alternative Names: Luveniq; LX 211; LX 212; LX 214; Voclosporin ophthalmic solution - Aurinia Pharmaceuticals; VOSLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Isotechnika
- Developer Aurinia Pharmaceuticals; Lux Biosciences
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Ciclosporins; Eye disorder therapies; Skin disorder therapies; Small molecules; Urologics; Vascular disorder therapies
- Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Dry eyes
- Discontinued Blepharitis; Uveitis
Most Recent Events
- 02 Nov 2020 Suspended - Phase-II/III for Dry eyes in USA (Ophthalmic)
- 02 Nov 2020 Interim efficacy and adverse events data from a phase II/III AUDREY trial in dry eyes released by Aurinia Pharmaceuticals
- 08 Oct 2020 Aurinia Pharmaceuticals completes the phase II/III AUDREY trial for Dry eyes in USA (Ophthalmic) (NCT04147650)